Ibandronic Acid Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0020 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
22/11/2022 
SmPC and PL 
To update section 4.8 of the SmPC to add the adverse 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
reaction hypocalcaemia with a frequency uncommon for the 
strength 150 mg (EU_003 and EU_004) in order to align 
the PI with the outcome of the PSUSA/00001702/202106 of 
the reference product Bonviva. The Package leaflet is 
updated accordingly. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
N/0019 
Minor change in labelling or package leaflet not 
23/07/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0018 
A.7 - Administrative change - Deletion of 
07/01/2021 
23/07/2021 
Annex II and 
manufacturing sites 
PL 
IB/0017 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/08/2020 
23/07/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IB/0016 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
10/11/2016 
30/10/2017 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0015 
A.7 - Administrative change - Deletion of 
25/04/2016 
15/09/2016 
Annex II and 
manufacturing sites 
PL 
IAIN/0014 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/12/2015 
15/09/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0013/G 
This was an application for a group of variations. 
24/09/2015 
15/09/2016 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
Additionally, the MAH has made editorial changes to the 
Product Information in Czech, Swedish and Slovenian. 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0012 
Renewal of the marketing authorisation. 
23/04/2015 
25/06/2015 
Annex II 
Based on the CHMP review of the available information and 
on the basis of a re-evaluation of the benefit risk balance, 
the CHMP is of the opinion that the quality, safety and 
efficacy of this medicinal product continues to be 
adequately and sufficiently demonstrated and therefore 
considered that the benefit risk profile of Ibandronic Acid 
Teva continues to be favourable. The CHMP was also of the 
opinion that the renewal can be granted with unlimited 
validity. 
T/0011 
Transfer of Marketing Authorisation from Teva 
03/11/2014 
01/12/2014 
SmPC, 
Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
IA/0010 
B.II.b.4.b - Change in the batch size (including batch 
16/04/2014 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/03/2014 
27/06/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0008/G 
This was an application for a group of variations. 
06/09/2013 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/06/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/06/2013 
27/06/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
IAIN/0005/G 
This was an application for a group of variations. 
14/06/2012 
29/10/2012 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0004/G 
This was an application for a group of variations. 
10/01/2012 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the currently approved batch 
size 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
IB/0003/G 
This was an application for a group of variations. 
20/10/2011 
10/05/2012 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer responsible for 
batch release 
II, Labelling 
and PL 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/07/2011 
n/a 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
A20/0001 
Pursuant to Article 20 of Regulation (EC) No 
14/04/2011 
29/06/2011 
SmPC, Annex 
Please refer to the Assessment Report: H-1195-RAR-A20-
726/2004, the European Commission requested on 
II and PL 
0001_en 
19 October 2010, the opinion of the CHMP on 
measures necessary to ensure the safe use of the 
above mentioned medicinal product further to the 
CHMP review on the currently available data in 
relation to the incidence of atypical stress fractures 
and its impact on the risk-benefit balance. 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
